[The effect of antitumor chemotherapy on the lipid spectrum of the erythrocyte membranes in lung cancer patients].
The lipid spectrum of erythrocyte membranes was studied by thin-layer and gas-liquid chromatography in patients with lung cancer in the process of antineoplastic cytostatic chemotherapy. The control group of examined subjects was formed of healthy volunteers. During a course of antineoplastic polychemotherapy according to the CAM scheme (cyclophosphan, adriamycin, methotrexate) disorders of the erythrocyte membrane lipid spectrum in patients with II-IV stage lung cancer remained or became still more manifest.
Novitskiĭ
V V
VV
Institute of Pharmacology, Tomsk Research Center, Siberian Branch, Russian Academy of Medical Sciences, Russia.
Stepovaia
E A
EA
Bazhenova
N G
NG
Gol'dberg
V E
VE
Kolosova
M V
MV
Saprykina
E V
EV
Sokolova
I B
IB
Koreshkova
K G
KG
Bulavina
Ia V
IaV
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D002855:Chromatography, Thin Layer; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004910:Erythrocyte Membrane / Q000187:drug effects* / Q000378:metabolism; D005410:Flame Ionization; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008563:Membrane Lipids / Q000097:blood*; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D009367:Neoplasm Staging; D013997:Time Factors
D008563:Membrane Lipids; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate